title: Degradative enzymes modulate airway responses to intravenous neurokinins A and B.
abstract: We studied the effects of the neutral endopeptidase (NEP) inhibitor thiorphan (1.7 mg/kg iv) and the angiotensin-converting enzyme (ACE) inhibitor captopril (5.7 mg/kg iv) on airway responses to rapid intravenous infusions of neurokinin A (NKA) and neurokinin B (NKB) in anesthetized, mechanically ventilated guinea pigs. The dose of NKA required to decrease pulmonary conductance to 50% of its base-line value (ED50GL) was fivefold less (P less than 0.0001) in animals treated with thiorphan compared with controls. NKA1-8, a product resulting from cleavage of NKA by NEP, had no bronchoconstrictor activity. Similar results were obtained by using NKB as the bronchoconstricting agent. Captopril had no significant effect on airway responses to NKA or NKB. In contrast, both thiorphan and captopril decrease the ED50GL for substance P (SP). We also compared the relative bronchoconstrictor potency of NKA, NKB, and SP. In control animals, the rank order of ED50GL values was NKA much less than NKB = SP. NKA also caused a more prolonged bronchoconstriction than SP or NKB. Thiorphan had no effect on the rank order of bronchoconstrictor potency, but in animals treated with captopril, the rank order of ED50GL values was altered to NKA less than SP less than NKB. These results suggest that degradation of NKA and NKB by NEP but not by ACE is an important determinant of the bronchoconstriction induced by these peptides. The degradation by ACE of SP but not NKA or NKB influences the observed relative potency of the three tachykinins as bronchoactive agents.
authors.affiliation: Department of Medicine, Beth Israel Hospital, Boston, Massachusetts.
authors.forename: S A
authors.initials: SA
authors.lastname: Shore
authors.forename: J M
authors.initials: JM
authors.lastname: Drazen
mesh_terms: D000818:Animals; D001980:Bronchi / Q000187:drug effects*; D002216:Captopril / Q000494:pharmacology*; D006168:Guinea Pigs; D007262:Infusions, Intravenous; D008297:Male; D015260:Neprilysin / Q000037:antagonists & inhibitors; D015288:Neurokinin A / Q000008:administration & dosage / Q000494:pharmacology*; D015287:Neurokinin B / Q000008:administration & dosage / Q000494:pharmacology*; D015244:Thiorphan / Q000494:pharmacology*; D014132:Trachea / Q000187:drug effects*
chemical_list: D015288:Neurokinin A; D015287:Neurokinin B; D002216:Captopril; D015244:Thiorphan; D015260:Neprilysin